Clinical trials confirmed THC/CBD spray works for one-third of treatment-resistant MS spasticity patients
In phase III clinical trials, approximately one-third of MS patients with treatment-resistant spasticity responded to THC/CBD oral spray, with sustained benefit and no significant effects on cognition or mood after 50 weeks.
Quick Facts
What This Study Found
This review summarized the phase III clinical trial program for THC/CBD oromucosal spray in MS spasticity. A meaningful proportion of patients with treatment-resistant spasticity achieved clinically relevant improvement with active treatment versus placebo.
A 4-week initial trial of therapy proved useful for identifying which patients would respond. After 50 weeks of treatment in a post-approval study, approximately two-thirds of patients, physicians, and caregivers reported improvement in spasticity. Importantly, the post-approval study showed no statistically significant effect on cognition or mood compared to placebo.
The spray was well tolerated, with no evidence of effects typically associated with recreational cannabis use. Responders experienced relief not only from spasticity but also from associated symptoms including spasms, urinary dysfunction, and sleep disturbances.
Key Numbers
Approximately one-third of treatment-resistant patients responded. Two-thirds reported improvement at 50 weeks. No significant effect on cognition or mood. Associated symptom relief included spasms, urinary dysfunction, and sleep.
How They Did This
Review of pivotal phase III clinical trials and a post-approval clinical trial for THC/CBD oromucosal spray in MS spasticity.
Why This Research Matters
These trial results established the clinical evidence base for regulatory approval of THC/CBD spray in multiple countries. The finding that cognition and mood were unaffected after nearly a year of use addressed key safety concerns about long-term cannabis-based medicine use.
The Bigger Picture
The enriched-design trial strategy (identifying responders before randomization) set a precedent for how cannabis-based medicines could be tested and prescribed: start with a trial period, continue only in those who respond. This approach maximizes benefit while minimizing exposure in non-responders.
What This Study Doesn't Tell Us
The enriched design, while clinically practical, can overestimate effect sizes. Response rates of one-third mean two-thirds do not benefit. The specific responder characteristics were not well defined.
Questions This Raises
- ?Can clinicians predict who will respond before starting the trial period?
- ?What happens after multiple years of continuous use?
- ?Would higher doses benefit non-responders, or have they simply reached the ceiling of cannabinoid effect?
Trust & Context
- Key Stat:
- No effect on cognition or mood after 50 weeks of THC/CBD spray use
- Evidence Grade:
- Summary of phase III clinical trials, the gold standard of evidence for medication approval.
- Study Age:
- Published in 2014.
- Original Title:
- Advances in the management of multiple sclerosis spasticity: recent clinical trials.
- Published In:
- European neurology, 72 Suppl 1, 9-11 (2014)
- Authors:
- Fernández, Oscar(2)
- Database ID:
- RTHC-00795
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What percentage of MS patients respond to THC/CBD spray?
Approximately one-third of patients with treatment-resistant spasticity achieved clinically relevant improvement in phase III trials. A 4-week trial period helps identify who will benefit.
Does long-term THC/CBD spray affect thinking or mood?
A 50-week post-approval study found no statistically significant effects on cognition or mood compared to placebo, addressing concerns about long-term use of a cannabis-based medicine.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00795APA
Fernández, Oscar. (2014). Advances in the management of multiple sclerosis spasticity: recent clinical trials.. European neurology, 72 Suppl 1, 9-11. https://doi.org/10.1159/000367616
MLA
Fernández, Oscar. "Advances in the management of multiple sclerosis spasticity: recent clinical trials.." European neurology, 2014. https://doi.org/10.1159/000367616
RethinkTHC
RethinkTHC Research Database. "Advances in the management of multiple sclerosis spasticity:..." RTHC-00795. Retrieved from https://rethinkthc.com/research/fernandez-2014-advances-in-the-management-2
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.